Aclaris Therapeutics company info

What does Aclaris Therapeutics do?
Aclaris Therapeutics (NASDAQ:ACRS) specializes in developing novel drug candidates and therapies in dermatology and immunology. The company focuses on addressing unmet needs for patients with conditions stemming from immuno-inflammatory responses. Aclaris is actively involved in a range of projects, emphasizing innovation in the treatment of skin diseases and hair loss, among other health concerns. Their objectives include advancing their pipeline products through clinical trials with the goal of achieving market approval and creating effective treatments that improve patients' quality of life. Through rigorous research and development efforts, Aclaris aims to bring transformative therapies to the market, targeting conditions with significant patient impact.
Aclaris Therapeutics company media
Company Snapshot

Is Aclaris Therapeutics a public or private company?

key
Ownership
Public

How many people does Aclaris Therapeutics employ?

people
Employees
89

What sector is Aclaris Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Aclaris Therapeutics?

location pin
Head Office
Pennsylvania, United States

What year was Aclaris Therapeutics founded?

founded flag
Year Founded
2012
What does Aclaris Therapeutics specialise in?
/Dermatological Therapies /Immunology Treatments /Inflammatory Medicine /Skin Conditions /Clinical Research /Pharmaceutical Services

What are the products and/or services of Aclaris Therapeutics?

Overview of Aclaris Therapeutics offerings
ATI-450, an oral MK2 inhibitor for treating rheumatoid arthritis.
A-101 45% Topical Solution for common warts (verruca vulgaris).
ATI-1777, an investigational soft JAK 1/3 inhibitor applied topically for atopic dermatitis.
ATI-2138, an oral ITK inhibitor for T-cell mediated diseases, including psoriasis.

Who is in the executive team of Aclaris Therapeutics?

Aclaris Therapeutics leadership team
  • Dr. Neal S. Walker D.O., M.D.
    Dr. Neal S. Walker D.O., M.D.
    Co-Founder, President, Chairman & Interim CEO
  • Dr. Joseph  Monahan Ph.D.
    Dr. Joseph Monahan Ph.D.
    Chief Scientific Officer
  • Mr. Kevin  Balthaser
    Mr. Kevin Balthaser
    Chief Financial Officer
  • Mr. Matthew  Rothman J.D.
    Mr. Matthew Rothman J.D.
    General Counsel & Corporate Secretary
  • Dr. Jon  Jacobsen Ph.D.
    Dr. Jon Jacobsen Ph.D.
    Senior Vice President of Chemistry
  • Mr. James  Loerop
    Mr. James Loerop
    Chief Business Officer